Jump to content

Baby Banker

Members
  • Content Count

    109
  • Joined

  • Last visited

  • Days Won

    5
  • Country

    United States

Baby Banker last won the day on September 25 2019

Baby Banker had the most liked content!

Profile Information

  • Gender
    Not Telling
  • Occupation
    Blood Bank Systems Analyst

Recent Profile Visitors

1,481 profile views
  1. You should also address the zygosity of the cells used to rule out. Do you do selected cell panels where you use cells from different panels (after you've done a standard panel)?
  2. Change Control started in Blood Bank in our lab, but now the whole laboratory uses the process.
  3. We are on SafeTrace Tx version 3.13. We upgraded last June. Based on my experience with Haemonetics and other vendors, I don't think the FDA would allow a vendor to be ten years without an upgrade.
  4. I wondered if you were testing fecal occult blood.
  5. We use issue to mean dispensing the product to staff who will take it to the patient's location. We don't use the term collected except in the context of drawing specimens. I suspect this is a British English vs. American English 'issue.'
  6. We have an anonymous phone line as part of our Corporate Compliance Department. You probably do as well.
  7. As noted above, irradiation changes the product code. For example when E0226 is irradiated it becomes E0224. Our computer system changes the product code and prints the appropriate label. Irradiated is part of the description of the new product code and prints on the new label. The sticker you asked about is similar to one we used back in the 'Codabar Days.' However it does not suffice on it's own now.
  8. We tube blood, but only to our CV Lab. We do a transfer in our BECS, which is SafeTrace Tx.
  9. Pneumatic tube systems generally have a way to set a priority based on location. You should check to make sure carriers coming from the Blood Bank have the highest priority available.
  10. We do. We use plain clear zip lock bags. We have used biohazard bags in the past. We stopped because there was a concern that the patients might think we were giving them biohazardous units.
  11. Looking back over, I realized that I did not specify that the patients I am talking about are the ones on chronic transfusion therapy and are transfused about every three to five weeks. They have all either had a stroke or have been identified as being at high risk for stroke.
  12. We limit our matching to a group that is generally manageable. It has been some time ago since I looked at their recommendation, but the Sickle Cell Foundation was recommending matching further than we do. We do find that these patients develop 'warm autoantibodies' which I think are or may be a reflection of the myriad other antigens that we do not match. That being said, our practice has been successful in preventing stroke overall in a disadvantaged and usually overlooked (in my area) group of children. We have done a pretty good job of indoctrinating the patients and their families to get in touch with us when our patients go to another facility.
  13. We do our best to avoid them having multiple antibodies by...wait for it...antigen matching. I agree with Ex-Limey that our sicklers who are prone to stroke have more than enough going on without having even a mild reaction. We have had a few patients with hyperhemolysis and they are the very devil to treat. The ideal would be to stop transfusions, but that is a very difficult decision to make with these patients. Also, since we are a pediatric facility, the family may decide to go elsewhere to continue transfusions.
×
×
  • Create New...

Important Information

We have placed cookies on your device to help make this website better. You can adjust your cookie settings, otherwise we'll assume you're okay to continue.